Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival ...

Pfizer’s Braftovi regimen nearly doubles median progression-free survival in metastatic colorectal cancer: New York Tuesday, June 2, 2026, 10:00 Hrs [IST] Pfizer Inc. announced ...

Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, ...

In this video, Suneel Kamath, MD, discussed the approval of encorafenib (Braftovi, Array BioPharma) in combination with cetuximab (Erbitux, ImClone) and fluorouracil-based chemotherapy in metastatic ...

Phase 2 study to evaluate combination therapy in patients with metastatic colorectal cancer, targeting β-catenin-driven immune exclusion in liver ...

mCRC treatment involves balancing efficacy, tolerability, and patient goals, with fruquintinib, regorafenib, and trifluridine-tipiracil as key therapies. Oncology pharmacists are essential in ...

Preliminary results of fruquintinib in combination with FOLFIRI as second-line treatment for RAS-mutant metastatic colorectal cancer: A prospective, single-center phase 2 study. Efficacy and safety of ...

Three scientists working in a laboratory. They are bending over a table looking at data and a paper. Heather Candrilli, 36, a mother of two, is battling metastatic colon cancer, underscoring the ...

Resection of liver metastases is considered the only treatment with curative potential for patients with metastatic colorectal cancer to the liver (CRLM). However, only a minority of patients with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...